Peter R. Briggs

PO Box 72, 823-865 Centre Road, 
Bentleigh, VIC, AU 
PO Box 72, 823-865 Centre Road, 
Bentleigh, VIC, AU 

Overview

Peter Briggs practices practicing medicine in Bentleigh, Australia.

His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Metastases.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

PO Box 72, 823-865 Centre Road, Bentleigh, VIC 3165, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Biological, Drug
Study Drugs: rAd-IFN, Celecoxib, Gemcitabine
Study Phase: Phase 3
A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)
A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)
Enrollment Status: Unknown
Publish Date: April 21, 2023
Intervention Type: Drug
Study Drugs: Tremelimumab, Durvalumab
Study Phase: Phase 2
View 1 Less Clinical Trial

11 Total Publications

Soil respiration-driven CO2 pulses dominate Australia's flux variability.
Soil respiration-driven CO2 pulses dominate Australia's flux variability.
Journal: Science (New York, N.Y.)
Published: March 30, 2023

Frequently Asked Questions about Peter R. Briggs

Is Peter R. Briggs a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Peter R. Briggs is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Peter R. Briggs participate in research or clinical trials?

Yes. Peter R. Briggs has published 11 articles and abstracts on conditions like Lung Cancer. You can view a list of Peter R. Briggs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Briggs's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile